– UK, London – AstraZeneca PLC (LON: AZN | STO: AZN | Nasdaq: AZN) today announced the appointment of Andreas Rummelt to its Board as a Non-Executive Director, effective 1 August 2021.
“We are delighted to welcome Andreas to AstraZeneca and look forward to working with him. His extensive experience of the pharmaceutical industry and in particular his technical R&D, manufacturing and quality assurance expertise, together with his deep knowledge of Alexion, will enable him to make a significant contribution to the Board’s work.” said Board Chairman, Leif Johansson.
About Andreas Rummelt
Dr. Andreas Rummelt has more than 20 years of experience in executive management positions in the pharmaceutical industry. Dr. Rummelt has been a member of the Board of Alexion since 2010. His international career has focused on technical research and development, manufacturing and quality, as well as a period leading a generics business as Chief Executive Officer. He is now Chairman and Managing Partner of InterPharmaLink AG, a management consulting firm based in Basel, Switzerland.
Dr. Rummelt was Group Head of Technical Operations and Quality at Novartis and, from 2006 until 2010, served as a member of the Executive Committee there. He originally joined Sandoz Pharma in Basel, Switzerland in 1985 and held various positions of increasing responsibility in Pharma Development, including Head of Worldwide Technical Research and Development. From 1999, Dr. Rummelt served as Global Head of Technical Operations and Quality of the Pharmaceuticals Division of Novartis, and from 2004 to 2008, as Global Chief Executive Officer of Sandoz, the Generics Division of Novartis.
Dr. Rummelt has served as a Director of Alexion Pharmaceuticals, Inc. since 2010 and is a member of the boards of various privately-held biotech and pharmaceutical companies in Europe. He is also a member of the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership based in Geneva, Switzerland.
Dr. Rummelt is a pharmacist and earned his Ph.D. in pharmaceutical sciences from the University of Erlangen-Nuremberg, Germany. He received his executive training in general management and leadership from IMD in Lausanne, Switzerland; INSEAD in Fontainebleau, France; and Harvard Business School in Cambridge, MA in the US.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
For more information: https://www.astrazeneca.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.